Unraveling a Tangle of Confusion Over ADHD Medication
Let’s set the record straight: Stimulant medication is safe for most adults with ADHD and can protect against addiction and accidents.
ADHD Medication for Adults: Article Contents
Nearly half of the 15.5 million American adults with ADHD were not diagnosed as children.1 A surge in later-life diagnoses means more people are now exploring treatment options. And they have questions.
Medications, particularly stimulants, remain the most researched and effective treatments for ADHD. While questions about their efficacy, safety, and benefits should always be answered by a doctor, this guide can help you understand ADHD medications and their potential role in your treatment plan.
How ADHD Medications Work
ADHD is associated with lower dopamine and norepinephrine activity in the prefrontal cortex. These neurotransmitters modulate attention, motivation, and impulse control. Stimulant medications increase signaling by and to these neurotransmitters by boosting release of the chemicals and blocking reuptake, producing longer lasting effects.
Non-stimulants are another category of ADHD medications. These include atomoxetine, viloxazine, and off-label bupropion, which boost dopamine and norepinephrine. (Viloxazine also acts on serotonin receptors.) The non-stimulants guanfacine and clonidine don’t raise neurotransmitter levels but stimulate the alpha-2A receptors involved in impulse control, attention, and emotional regulation.
Which Medication to Choose?
Stimulants are generally more effective than non-stimulant medications for ADHD. Of the two stimulant classes, amphetamine and methylphenidate, the former shows the strongest results2, while methylphenidate outperforms non-stimulants.3 4 Ultimately, the best medication is the one that controls your symptoms with the fewest side effects.
💡Free! ADHD Treatment Guide for Adults
When Will the Medication Start Working?
Stimulants’ effects appear within three days. Many non-stimulants take weeks to reach effective levels and start working. Some, however, particularly bupropion and atomoxetine, act on neurotransmitters right away; people taking one of these non-stimulants may notice improvements within hours.
Getting the Dose Right
In my clinical experience, many people who try stimulants for the first time experience a “honeymoon period,” during which the benefits are greater in the first few weeks than they are thereafter, even with dose adjustments. Some argue this reflects physiological “tolerance,”, but it may instead be the euphoria and relief of improvement after a lifetime of frustration. Be aware of this phenomenon and aim for a sustainable dose that works for you over time.
If the benefits of medication are minimal and side effects are low, your provider should titrate upward and monitor over three-day intervals. You can judge a medication’s efficacy through:
- ADHD symptom rating scales. These are useful, but responses should be interpreted cautiously, since they’re self-reported.
- Personal measures. You track concrete, time-based improvements (e.g., time spent answering emails or reading a book).
- Collateral information. What have your friends, family, and providers observed?
Note that small dips in attention, focus, and alertness throughout the day are normal. Attempting to medicate your way out of these lulls (i.e., siesta time) may be counterproductive.
Read: 11 Steps to Prescribing and Using ADHD Medication Effectively
The Benefits of ADHD Treatment
The benefits of the correct ADHD medication go beyond improving focus, productivity, and emotional regulation. Treating ADHD reduces other risk factors; for example, studies show that adherent treatment decreases the overall likelihood of substance use-related problems.5
Untreated ADHD, on the other hand, doubles the risk of developing a substance use disorder.6 Evidence indicates that the vast majority of individuals with ADHD do not become addicted to their prescribed medications.7
Is a Dose Ever Too High?
A dose is too high only if it causes problematic side effects. That said, many prescribers and insurers won’t excel labeled doses. If your doctor’s dosing decisions are driven by milligrams rather than outcomes, consider getting a second opinion.
ADHD Medications: Possible Side Effects
Short- and long-term ADHD medication side effects are typically addressed by lowering the dose. Some fade with time. Mild side effects may include:
- Anxiety
- Tremors
- Irritability and/or agitation
- Sweating
- Dry mouth
- Insomnia
- Appetite suppression
- Increased heart rate/blood pressure
Rare But Serious Side Effects of ADHD Medications
The vast majority of people on ADHD medications will never experience the following serious side effects. Nevertheless, here’s what you should know.
Cardiac Effects
Most studies find no significant adverse cardiovascular effects from ADHD medications. A recent study found a link between long-term treatment and hypertension or arterial disease8, but the overall risk was low. The study did not find increases in arrhythmias, heart failure, heart attacks, or strokes. Importantly, it did not prove causality.
For the average patient without serious heart problems, the benefits of ADHD medication exceed the small cardiovascular risk, as long as blood pressure and heart rate are monitored. People with pre-existing or a strong family history of heart disease or uncontrolled hypertension may need special evaluation. Lifestyle factors (e.g., smoking, inactivity, stress) can amplify risk far more than medication and should be addressed.
Psychosis
Stimulant-induced psychosis is rare, and studies have found inconsistent incidence rates. A study that followed about 222,000 teens and young adults taking ADHD stimulants found that 1 in every 660 developed psychoses.9 Other studies have found no link between prescribed methylphenidate use and psychosis.10
A 2025 study found no causality between stimulant use and psychosis, instead noting that their association may reflect underlying patient characteristics, not the stimulants.11 People who experience psychosis on stimulants should discontinue use and take an antipsychotic, which can help resolve symptoms within days.
Optimizing ADHD Treatment
Combining short- and long-acting stimulants or adding a non-stimulant can extend coverage and reduce side effects. ADHD is managed most effectively when you combine medication with proper nutrition, exercise, adequate sleep, and therapy to support executive functioning and emotional regulation.
ADHD Medication for Adults: Next Steps from ADDitude
John Kruse, M.D., Ph.D., is a neuroscientist, psychiatrist, and author.
SUPPORT ADDITUDE
Thank you for reading ADDitude. To support our mission of providing ADHD education and support, please consider subscribing. Your readership and support help make our content and outreach possible. Thank you.
View Article Sources
1 Staley, B. S., Robinson, L. R., Claussen, A. H., Katz, S. M., Danielson, M. L., Summers, A. D., Farr, S. L., Blumberg, S. J., & Tinker, S. C. (2024). Attention-Deficit/Hyperactivity Disorder Diagnosis, Treatment, and Telehealth Use in Adults – National Center for Health Statistics Rapid Surveys System, United States, October-November 2023. MMWR. Morbidity and Mortality Weekly Report, 73(40), 890–895. https://doi.org/10.15585/mmwr.mm7340a1
2 Cortese, S., Adamo, N., Del Giovane, C., Mohr-Jensen, C., Hayes, A. J., Carucci, S., Atkinson, L. Z., Tessari, L., Banaschewski, T., Coghill, D., Hollis, C., Simonoff, E., Zuddas, A., Barbui, C., Purgato, M., Steinhausen, H. C., Shokraneh, F., Xia, J., & Cipriani, A. (2018). Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. The Lancet. Psychiatry, 5(9), 727–738. https://doi.org/10.1016/S2215-0366(18)30269-4
3 Faraone S. V. (2009). Using Meta-analysis to Compare the Efficacy of Medications for Attention-Deficit/Hyperactivity Disorder in Youths. P & T : a peer-reviewed journal for formulary management, 34(12), 678–694.
4 Bellato, A., Perrott, N. J., Marzulli, L., Parlatini, V., Coghill, D., & Cortese, S. (2025). Systematic Review and Meta-Analysis: Effects of Pharmacological Treatment for Attention-Deficit/Hyperactivity Disorder on Quality of Life. Journal of the American Academy of Child and Adolescent Psychiatry, 64(3), 346–361. https://doi.org/10.1016/j.jaac.2024.05.023
5 Zhang, L., Zhu, N., Sjölander, A., Nourredine, M., Li, L., Garcia-Argibay, M., Kuja-Halkola, R., Brikell, I., Lichtenstein, P., D’Onofrio, B. M., Larsson, H., Cortese, S., & Chang, Z. (2025). ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ (Clinical research ed.), 390, e083658. https://doi.org/10.1136/bmj-2024-083658
6 Wilens, T. E., Martelon, M., Joshi, G., Bateman, C., Fried, R., Petty, C., & Biederman, J. (2011). Does ADHD predict substance-use disorders? A 10-year follow-up study of young adults with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 50(6), 543–553. https://doi.org/10.1016/j.jaac.2011.01.021
7 Han B, Jones CM, Volkow ND, et al. Prescription Stimulant Use, Misuse, and Use Disorder Among US Adults Aged 18 to 64 Years. JAMA Psychiatry. 2025;82(6):572–581. doi:10.1001/jamapsychiatry.2025.0054
8 Zhang, L., Li, L., Andell, P., Garcia-Argibay, M., Quinn, P. D., D’Onofrio, B. M., Brikell, I., Kuja-Halkola, R., Lichtenstein, P., Johnell, K., Larsson, H., & Chang, Z. (2024). Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases. JAMA psychiatry, 81(2), 178–187. https://doi.org/10.1001/jamapsychiatry.2023.4294
9 Moran, L. V., Ongur, D., Hsu, J., Castro, V. M., Perlis, R. H., & Schneeweiss, S. (2019). Psychosis with methylphenidate or amphetamine in patients with ADHD. The New England Journal of Medicine, 380(12), 1128–1138. https://doi.org/10.1056/NEJMoa1813751
10 Zarchev, M., Bouter, D. C., & Grootendorst-van Mil, N. H. (2024). No association between methylphenidate use and psychotic experiences in a population-based sample of adolescents at risk of emotional and behavioral problems. Acta Psychiatrica Scandinavica, 149(2), 168–170. https://doi.org/10.1111/acps.13630
11 O’Hare, K., Byrne, J. F., Ramsay, H., Romaniuk, L., McGrath, J., Keating, D., Migone, M., O’Connor, K., Coss, N., Cannon, M., Cotter, D., Healy, C., & Kelleher, I. (2025). Stimulant medication use and risk of psychotic experiences. *Pediatrics, 155*(6), e2024069142. https://doi.org/10.1542/peds.2024-069142
